Anebulo Pharmaceuticals, Inc.
ANEB- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001815974
No open-market purchases or sales by Anebulo Pharmaceuticals, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Anebulo Pharmaceuticals, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 15
- +2 vs. Q3 2024
- Shares held
- 22.6M
- +15.2M (+207.3%) vs. Q3 2024
- Total value
- $37.3M
- +$23.1M (+163.2%) vs. Q3 2024
- New holders
- 2
- 6 more added
- Sold out
- 0
- 4 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ANEB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 19 | $6.81M |
| Q3 2025 | 21 | $55.5M |
| Q2 2025 | 18 | $32.5M |
| Q1 2025 | 18 | $29.4M |
| Q4 2024 | 15 | $37.3M |
| Q3 2024 | 13 | $14.2M |
| Q2 2024 | 13 | $20.0M |
| Q1 2024 | 15 | $21.0M |
| Q4 2023 | 14 | $17.6M |
| Q3 2023 | 12 | $21.6M |
| Q2 2023 | 12 | $16.5M |
| Q1 2023 | 10 | $19.8M |
| Q4 2022 | 12 | $17.1M |
| Q3 2022 | 11 | $19.2M |
| Q2 2022 | 9 | $24.3M |
| Q1 2022 | 10 | $29.5M |
| Q4 2021 | 10 | $25.8M |
| Q3 2021 | 9 | $27.5M |
| Q2 2021 | 9 | $28.7M |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Anebulo Pharmaceuticals, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| 22NW, LP | 15,467,300 | $26.0M | 16.39% | +10,101,010+188.2% | Added |
| Nantahala Capital Management, LLC | 3,036,325 | $5.10M | 0.36% | +2,525,252+494.1% | Added |
| Mangrove Partners | 2,525,252 | $3.64M | 0.43% | +2,525,252 | New |
| LVW Advisors, LLC | 632,516 | $1.06M | 0.13% | −8,523−1.3% | Reduced |
| Morgan Stanley | 419,994 | $705.6K | 0.00% | +20,775+5.2% | Added |
| Ikarian Capital, LLC | 157,720 | $265.0K | 0.08% | −142−0.1% | Reduced |
| Vanguard Group Inc | 154,036 | $258.8K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 91,341 | $153.5K | 0.00% | +3,551+4.0% | Added |
| King Luther Capital Management Corp | 59,662 | $100.2K | 0.00% | +59,662 | New |
| Boothbay Fund Management, LLC | 18,836 | $31.6K | 0.00% | −142−0.7% | Reduced |
| BlackRock, Inc. | 3,929 | $6.60K | 0.00% | +24+0.6% | Added |
| Tower Research Capital LLC (TRC) | 3,326 | $5.59K | 0.00% | +632+23.5% | Added |
| Bank of America Corp | 76 | $128 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 25 | $42 | 0.00% | −738−96.7% | Reduced |
| JPMorgan Chase & Co | 9 | $15 | 0.00% | 00.0% | Unchanged |